



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Preclinical Organotypic Models for the Assessment of Novel Cancer Therapeutics and Treatment

Citation for published version:

Ward, C, Meehan, J, Gray, M, Kunkler, I, Langdon, S, Murray, A & Argyle, D 2019, Preclinical Organotypic Models for the Assessment of Novel Cancer Therapeutics and Treatment. in F Bagnoli & R Rappuoli (eds), *Current Topics in Microbiology and Immunology*. Current Topics in Microbiology and Immunology. https://doi.org/10.1007/82_2019_159

Digital Object Identifier (DOI):

[10.1007/82_2019_159](https://doi.org/10.1007/82_2019_159)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Current Topics in Microbiology and Immunology

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Preclinical Organotypic Models for the Assessment of Novel Cancer Therapeutics and Treatment

Carol Ward ^{a,b,*} James Meehan ^{b,c} Mark Gray ^{a,b} Ian H Kunkler ^b Simon P Langdon ^b Alan Murray ^d David Argyle ^a

^a The Royal (Dick) School of Veterinary Studies and Roslin Institute, University of Edinburgh, Easter Bush, Roslin, Midlothian, Edinburgh, EH25 9RG, United Kingdom.

^b Cancer Research UK Edinburgh Centre and Division of Pathology Laboratories, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XU, United Kingdom.

^c Institute of Sensors, Signals and Systems, School of Engineering and Physical Sciences, Heriot-Watt University, Edinburgh, EH14 4AS, United Kingdom.

^d School of Engineering, Faraday Building, The King's Buildings, Mayfield Road, Edinburgh, EH9 3JL, United Kingdom.

*Corresponding author. Tel.: +44 131 5371763.

E-mail address: C.Ward@ed.ac.uk

James Meehan	j.meehan@hw.ac.uk	Tel.: +44 131 5371763.
Mark Gray	s9900757@sms.ed.ac.uk	Tel.: +44 131 5371763.
Ian Kunkler	iankunkler@yahoo.com	Tel.: +44 131 651 8606
Simon Langdon	simon.langdon@ed.ac.uk	Tel.: +44 131 5371763.
David Argyle	david.argyle@roslin.ed.ac.uk	Tel.: +44 131 650 6241
Alan Murray	Alan.Murray@ed.ac.uk	Tel.: +44 131 6505589

Abstract

The immense costs in both financial terms and pre-clinical research effort that occur in the development of anti-cancer drugs are unfortunately not matched by a substantial increase in improved clinical therapies due to the high rate of failure during clinical trials. This may be due to issues with toxicity, or lack of clinical effectiveness when the drug is evaluated in patients. Currently, much cancer research is driven by the need to develop therapies that can exploit cancer cell adaptations to conditions in the tumor microenvironment such as acidosis and hypoxia, the requirement for more-specific, targeted treatments, or the exploitation of 'precision medicine' that can target known genomic changes in patient DNA. The high attrition rate for novel anti-cancer therapies suggests that the pre-clinical methods used in screening anti-cancer drugs need improvement. This chapter considers the advantages and disadvantages of 3D organotypic models in both cancer research and cancer drug screening, particularly in the areas of targeted drugs and the exploitation of genomic changes that can be used for therapeutic advantage in precision medicine.

Introduction

The simple definition of “organoid” is “resembling an organ”, implying that it should contain more than one cell type that is typically found in the organ of its origin, demonstrate an organ specific function, and that the cells should show some degree of organization. However, given that in this case the “organ” being modelled is a tumor, most, if not all 3D models meet these criteria. 3D culture can encompass various types of model such as spheroids and organoids, (terms which are often used interchangeably), or explants. Arguably, xenografts are also a type of 3D culture that fits the tumor organoid definition. For sake of clarity, the various 3D systems meeting these criteria will be discussed here separately. For more information on the definition and historical perspective of organoid development, see Simian and Bissell 2017.

Although extensive funding supports cancer research each year, the majority of novel drugs and therapies fail to translate into clinical practice due to lack of success in clinical trials, either because of deficiencies in clinical efficacy, or issues with toxicity (Petsko, 2010; Arrowsmith, 2011). Approximately one drug in 5,000 - 10,000 tested will gain FDA approval, with attrition rates in oncology particularly high with only 5% of anti-cancer therapies successfully undergoing Phase I/II clinical trials (Zamboni et al. 2012, Ocana et al. 2011). This is despite strong and significant *in vitro* and *in vivo* preclinical data, suggesting that better pre-clinical methodologies are required to identify new therapeutics (Kamb, 2005; Caponigro et al. 2011; Singh and Ferrara 2012; Siolas and Hannon 2013). The assessment of novel effective anti-cancer compounds is a compromise between the use of high throughput, low cost testing strategies, and high cost, low throughput methods which may give better translational results.

Most preclinical studies into the efficacy of anti-cancer drugs use cancer cell lines to assess various parameters such as cell survival, proliferation, cell death, migration and invasion. 2D cultures are one of the most cost effective strategies for high throughput assays and are used to test large numbers of compounds and select those for further examination. These cell lines can be exploited to investigate the role of specific pathways, genes or molecules using technologies such as CRISPR

(Sander and Joung 2014; Ledford 2015), siRNA (Moore et al. 2010), or inducible transgenics (Pajic et al. 2000; Belteki et al. 2005; Saunders 2011; Xie et al. 2014). However, these systems lack the heterogeneity of the original tumor, since cell culture selects those clones that best proliferate and survive in culture conditions (Daniel et al. 2009; Hensley et al. 2016). Using a panel of cell lines of the cancer of interest, or from different tumors such as the NCI-60 panel, or the *de novo* expansion of cell lines from tumor tissue, can partially overcome this problem (Burdall et al. 2003; Langdon 2004); but 2D culture cannot replicate the complex stromal elements of tumors, interactions with immune cells, inflammatory mediators, growth factors or the acidic/hypoxic conditions found in the tumor microenvironment (TME) (Karar and Maity 2009; Hanahan and Weinberg 2011; Ward et al. 2013). Targeting the adaptations cancer cells adopt to survive in the tumor microenvironment, is currently a novel approach to the treatment of solid tumors, and more appropriate models are required to support this research (McAllister and Weinberg 2010; Pettersen et al. 2015).

3D *in vivo* models

a) Mouse xenografts

Following assessment in 2D model systems, candidate compounds move into *in vivo* studies: generally mouse xenografts growing human tumor cell lines in strains of immunocompromised mice. These have shown mixed efficacy in translating novel drugs into clinical use, and often reproducibility of results is poor (Sausville and Burger 2006; Boedigheimer et al. 2013); but they do allow *in vivo* monitoring of tumor growth, drug toxicity, efficacy and pharmacokinetic studies, and will reflect the oxygen and pH gradients found in solid tumors. However, some cell lines do not form xenografts, metastatic models are limited, and immune responses, which affect tumor growth are compromised. Although xenografts incorporate some stromal elements, they are murine rather than human (Daniel et al. 2009). Xenografts are selected for rapidity of growth, while human tumors can take years to progress clinically; therefore these models do not replicate the heterogeneity of

the original tumor. Many xenografts are implanted subcutaneously and therefore do not reproduce the specific microenvironment of the tumor under investigation (Politi and Pao 2011). Orthotopic xenografts enable tumor development in the organ of origin, this can allow evaluation in a preclinical tumor model which more closely mimics the disease process in humans. However these models can be more difficult to establish compared with subcutaneous implantation.

b) Genetically engineered mouse models (GEMMs)

Spontaneous or carcinogen generated tumors, reflect the stromal interactions and angiogenesis found with tumor progression, but in a murine system with functioning immune responses. In GEMMs, tumors originate in a group of cells as a consequence of germline or somatic mutations, and share the genetic heterogeneity and histopathology of human tumors. They allow expression of oncogenes in a tissue-specific manner as well as conditional expression or deletion of oncogenes and tumor suppressors, allowing many cancers to be modelled (Sharpless and Depinho 2006; Politi and Pao 2011). GEMMs are also useful to model treatment resistance, chemotherapy enhancement, co-treatments and biomarker validation (Pietras and Hanahan 2005; Bell-McGuinn et al. 2007; Faca et al. 2008; Pitteri et al. 2009; Bellmunt et al. 2010; Polti et al. 2010). Several studies show that GEMMs model both the TME and stroma more accurately than xenografts (Olive et al. 2009; Graves et al. 2010), and better replicate the sensitivity of cancer to systemic therapy in clinical trials (Singh et al. 2010; Chen et al. 2012). However, the model is still murine.

c) Patient-derived xenografts (PDXs)

PDXs, involving the transfer of patient-derived tumor tissue into immunocompromised mice, (Kopetz et al. 2012; Julien et al. 2012; Huang et al. 2014), show pathology, growth and metastatic outcomes that closely correspond to the original tumor, and sustain the original histological markers, gene expression profiles, and proliferation indices (DeRose et al. 2011; Dean et al. 2012; Tentler et al. 2012; Stewart et al. 2017). This means that experimental data can be complemented with

clinical information, such as response to treatment in the original patient. The use of PDXs is increasing in preclinical studies (Hidalgo et al. 2011; Tentler et al. 2012), in conjunction with ‘co-clinical trials’ which run preclinical PDX and clinical trials at the same time (Nardella et al. 2011). For example, one study demonstrated that PDXs developed from individual patient tumors could be used to select treatment options with an 88% response rate (Hidalgo et al. 2011). PDXs have also been used to model human phase II trials that can examine differences in therapy responses across different cancers (Townsend et al. 2016; Byrne et al. 2017). PDX models have now superseded the NCI-60 panel as the gold standard for cancer research because of the preservation of heterogeneity (Leford, 2016).

Whilst this system is more robust, PDXs do have some shortcomings. Passaging is time consuming and some human stromal tumor elements are progressively lost over time. The rate of engraftment is poor for some cancer types such as prostate and ER⁺ breast cancer (DeRose et al. 2011; Lawrence et al. 2013) and tissue from needle biopsies is often inadequate for growth. There is still deficiency in immune responses and increased growth rate of tumors compared with human cancers (Rayal et al. 2012; Huang et al. 2014), although tumor growth and drug validation in these models can take several months (Hidalgo et al. 2011; Gao and Chen 2015). The same tumor sample can produce PDXs which may differ in genetics, or cell-surface markers, depending on the mouse strains used for tumor growth (Klco et al. 2014). The ratio of cancer cells to stromal cells can also drift; for example, pancreatic ductal adenocarcinomas (PDAs), contain high numbers of stromal cells (Guillaumond et al. 2013; Beloribi-Djefafia et al. 2015; Delitto et al. 2015), but because cancer cells multiply at a greater rate than stromal cells, stromal/cancer cell interactions change as cell ratios change (Martinez-Garcia et al. 2014). A recent study of 1,100 PDX models across 24 types of cancer showed sizable phenotypic and genomic changes between the progression of PDX models and human cancers, with PDXs developing both chromosome and gene copy number alterations during passages (Ben-David et al. 2017), which could influence the response to drug treatment. Metabolic reprogramming has been identified as a key hallmark of cancer

(Hanahan and Weinberg 2011), leading to increased interest in targeting specific enzymes as a novel therapeutic strategy in this disease. However, studies using human lung cancer tissue, show that both glycolysis and glutaminolysis are increased when human lung tumor tissue is cultured in PDX models (with murine stroma) when compared with the same tissue cultured with human stroma (using tissue slices), implying that PDX models may not be predictive of patient responses in the context of drugs which target tumor metabolism (Lane et al. 2016).

PDXs are not suitable for high throughput screening, or genetic manipulation (Gao and Chen 2015), but are extremely useful in situations where primary tumor material is scarce or rare, allowing long-term culture of much more diverse and heterogeneous tumor samples (Zhang et al. 2013). They can be developed from treatment resistant or recurrent tumor tissue (Aparicio et al. 2015; Townsend et al. 2016; Stewart et al. 2017), allowing the mechanisms involved to be explored. Various depositories of diverse treated/untreated tumor PDXs have been produced or are being developed, (EuroPDX consortium, the Public Repository of Xenografts, and the National Cancer Institute Patient-derived Models Repository) some of which are open source, such as that provided by Stewart et al., encompassing pediatric solid tumors, from 168 patients and 12 cancer types (Klco et al. 2014; Gao et al. 2015; Stewart et al. 2017; Townsend et al. 2016; Bruna et al. 2016).

d) Improving animal models

Animal models have been improved by ‘humanizing’ some aspects of the host, introducing human stromal elements or immune cells and thus humanizing the TME to some extent and allowing new immunotherapies to be explored (Proia, 2006; Vudattu et al. 2014; Morton et al. 2016). Such methods have been used to engineer the primary tumor environment, or mimic metastatic niches in breast and prostate cancers (Wang et al. 2010; Thibaudeau et al. 2014; Hesami et al. 2014; Holzapfel et al. 2014). One group has reported humanizing immunocompromised mice using aspirated hematopoietic stem and progenitor cells from bone marrow biopsies taken from cancer patients (Werner-Klein et al. 2014). However, the main obstacles to the

use of animal models remain high cost and low throughput. The pros and cons of these animal models are outlined in Table 1.

3D *in vitro* models

Xenograft models can have long latency periods; PDXs are maintained in a murine host and the availability and access to fresh human tumor tissue is a limiting factor for many researchers. Further, the trend in ethical research is to try to limit the use of animals wherever possible. There is therefore, a strong need for low cost, high throughput, clinically and physiologically relevant models for cancer research. Several studies have illustrated that 3D gene signatures can predict prognosis in several independent datasets (Fournier et al. 2006; Martin et al. 2008), suggesting that 3D *in vitro* ‘organoid’ models may help bridge the gap between pre-clinical translation and clinical trials.

Cancer stem cells (CSCs) form a subpopulation of cancer cells within a tumor that have been attributed with the ability to initiate primary, metastatic and recurrent tumor growth, and to be involved in treatment resistance (Mitra et al. 2015; Bomken et al. 2010). These cells have become an obvious focus for anti-cancer research. Tumor spheroids and organoids (see below) are both enriched for populations of CSCs (Lancaster and Knoblich 2014; Ishiguro et al. 2017; Capodanno et al. 2018). This allows for fast expansion of both organoid and spheroid culture systems, once the initial population of these 3D structures has been established. Further, both of these models can be used to harvest CSCs for research purposes (Ishiguro et al. 2017; Wang et al. 2018); an improvement on the traditional methodology for isolation and enrichment of these cells. CSCs from other mammals, for example from canine cancers, can also be obtained from this approach aiding studies in comparative and veterinary oncology (Capodanno et al; 2018).

a) Spheroids

Many cancer cell lines can be grown as small avascular spheroids using 3D scaffolds, hydrogels/collagen gels, or suspension culture as illustrated in Figure 1 (Frederich et al. 2009; Li and Lu 2011, Verjans et al. 2017). These generate a more

physiological model for cancer drug testing, displaying increased heterogeneity, cell-cell and cell-extracellular matrix (ECM) interactions, and differential gene/protein expression in comparison with monolayer cultures (Yamada and Cukierman 2007, Loessner et al. 2010). Drug and cell signaling responses differ when 3D and 2D methodologies are evaluated (dit Faute et al. 2002; Yamada and Cukierman, 2007; Loessner et al. 2010; Ravi et al. 2014). For example, in SKBR-3 breast cancer cells, the HER2 and HER3 receptors heterodimerise in 2D cultures, but HER2 forms homodimers in spheroids, with an increased response to HER2 inhibition (Pickl and Ries 2009). 3D cultures of human pancreatic, ovarian, liver and lung cancer cells exhibit increased chemoresistance in contrast to 2D culture via mechanisms that involve interactions with the ECM/TME (Sethi et al. 1999; Loessner et al. 2010; Longati et al. 2013; Ekert et al. 2014).

In solid tumors, rapid cell growth induces gradients of hypoxia and acidosis to develop, affecting sensitivity to radiation and chemotherapy (Gatenby et al. 2007; Correia and Bissell 2012; Ward et al. 2013). Although spheroids are grown under atmospheric oxygen tensions they develop O₂, CO₂, pH and metabolite gradients as they reach approximately 400 – 600 μ M in size, modelling the biology of solid tumors as illustrated in Figure 1 a and b. (Minchinton and Tannock 2006; Poussegur et al. 2006; Friedrich et al. 2009). These 3D models are now a necessity, particularly since novel treatment approaches targeting both pH_i regulation and/or glycolysis in hypoxic tumors are expected to be useful in combination with systemic and/or radiation therapy (Riffle et al. 2017). One reason for translational drug failure may be the lack of exploration of the effects of new drugs in conditions found in the TME.

Spheroids can be produced from cancer cells adapted by CRISPR, siRNA, shRNA or inducible transgenics and can incorporate other cell types such as fibroblasts or be embedded in ECM proteins to examine cell-cell and cell-matrix interactions, migration and invasion (Schmeichel and Bissell 2003; Heneweer et al. 2005; Hsiao et al. 2009; Ingram et al. 2010; Herrmann et al. 2014; McCracken et al. 2014; Ward et al. 2015) (Figure 2a). For example, the leading edge of pancreatic cancer cells contain RhoA-dependent projections which can be targeted by anti-metastatic treatments; these were first identified in 3D culture models (Timpson et

al. 2011). Tumor-derived human and murine breast cancer spheroids embedded into collagen, showed that cells expressing basal epithelial markers lead to collective invasion, both in 3D culture and in *in vivo* studies across breast cancer sub-types (Cheung et al. 2013).

Co-culture of spheroids and cancer-associated fibroblasts (CAFs) demonstrated that CAFs influence treatment resistance and invasion (Crawford et al., 2009; Li and Lu 2011; Horie et al. 2012; Straussman et al. 2012; Clark et al. 2013; Jaganathan et al. 2014; Kim et al. 2015). Co-culture systems have been used to replicate the metastatic niche of prostate cancer cells in bone using co-culture with osteoblasts and endothelial cells (Hsiao et al. 2009). Other 3D co-culture systems, using niches from lung or bone marrow stroma, demonstrated the role of TSP1 in tumor dormancy (Ghajar et al. 2013), while the relationship between brain endothelial cells and cancer stem cells have been examined in glioblastoma using 3D models of the perivascular niche (Infanger et al. 2013). A 3D co-culture of pancreatic stellate cells with PDA cells has produced a model that could be used to investigate PDA-stroma interactions in high throughput assays for drug screening (Ware et al. 2016). Spheroid generation using a defined size microwell assays with non-adherent hydrogels can generate uniform spheroids from cervical, breast, and head and neck squamous cells carcinoma cells within 3 to 6 days (Singh et al. 2015, 2016), making this system useful for high throughput assays.

b) Organoids

Organoids are created by culturing tissue samples with factors to stimulate the replication of pluripotent stem cells. It can take 3 weeks for organoids to grow to approximately 1 mm³ at which stage they contain the major cell types of the original tissue (Lancaster and Knoblich, 2014). Tumor organoids can be developed from tumor tissue or from isolated CSCs, and replicate many of the features of the primary tumor. For example, glioblastoma organoids from patient-derived CSCs demonstrated heterogeneity, a proliferative outer rim surrounding a hypoxic interior of senescent cells with dispersed quiescent radioresistant CSCs. Tumors generated

from these patient-derived organoids, showed the histological features of the parental tumor (Hubert et al. 2016).

Organoids can also be developed from murine tumor models. These have been used to explore the role of β -catenin and PI3K in colorectal cancer; a screen of inhibitors using this system associated 4EPB1 and Akt with cellular survival and motility in disease progression (Riemer et al. 2017). They have been developed from resected tissue and biopsies from colorectal (CRC) and prostate cancer, breast cancer, PDA, liver cancer, metaplastic epithelia from Barrett's esophagus, and also from circulating tumor cells (Sato et al. 2011; Gao et al. 2014; Boj et al. 2015; Weeber et al. 2015; Broutier et al. 2017; Schutte et al. 2017, Sachs et al. 2018).

Tumor organoids contain differentiated cell types, are biologically stable, can be frozen for later use and expanded once established (Sato et al. 2011; Sachs and Clevers 2014). Organoids allow the culture of tumors from individual patients, while maintaining the genetic and morphological diversity found within the corresponding patient tumor (van de Wetering et al. 2015; Weeber et al. 2015; Broutier et al. 2017; Pauli et al. 2017); for example, CRC organoids displayed a high degree of genetic similarity with the tumor tissue of origin (Schutte et al. 2017). PDA organoids generated from different stages of the cancer accurately replicated tumor progression based on transcriptomic and proteomic analysis (Boj et al. 2015) and demonstrated little change in histology, morphology, cytology or expression of differentiation markers from the originating tumor after 16 days in culture (Huang et al. 2015). It remains to be established whether these similarities are sustained long term. Although several studies suggest that mutation patterns are maintained during multiple passages (van de Wetering et al. 2015; Weeber et al. 2015; Fujii et al. 2016; Pauli et al. 2017; Schutte et al. 2017), one study using fluorescent markers showed that one color pre-dominated after 30–40 days in culture, suggesting clonal drift over time (Fujii et al. 2016). Organoids can also provide tissue for the study of rare cancers or those where cell line models are scarce. A further advantage is that control organoids from the same patient, can be developed from tumor-adjacent tissue. Several groups have reported the culturing of matched normal and tumor organoids

from treatment naïve surgical resections or biopsies (Boj et al. 2015; Van de Wetering et al. 2015).

Organoid cultures still lack tumor stroma, vasculature and immune cell interactions and those derived from early stage cancers appear to grow more quickly; therefore more malignant tumors may need optimized conditions for growth. They will not mirror the accumulated genetic mutations found in later stages of progression if developed from early stage tumors, but drug treatments should allow generation of treatment resistant models. This methodology may lead to personalization of drug testing for a plethora of cancers (Sachs and Clevers 2014), but the length of time for growth can vary depending on the cancer type. Costs may be also an issue and it is still unclear whether this method is applicable to all epithelial cancers.

Some of these issues are overcome by marrying organoid and PDX methodology. In one PDA model, tumor organoids were grown in orthotopic sites in mice, where they formed early-grade tumors that could develop and progress from local invasion to metastasis, while maintaining the histology of the original tumor tissue (Boj et al. 2016). This methodology was used to characterize specific alterations between pre-malignant and malignant states using transcriptomic and proteomic studies. Organoids grown from normal tissue, can be genetically engineered, using technologies such as CRISPR and therefore manipulated to study specific cancer mutations and cancer development and metastasis (Dekkers et al. 2013; Schwank et al. 2013; Matano et al. 2015; Fujii et al. 2016; Drost et al. 2017; Roper et al. 2017). As with spheroids, other cell types can be cultured with organoids. For example, co-culture of intraepithelial lymphocytes with murine intestinal organoids, showed lymphocytes entering and leaving organoids (Nozaki et al. 2016), but better tumor models will be achieved with the co-culture of stromal elements, particularly in tumors such as PDA, where the stroma is particularly important.

Organoids have been extremely useful in the study of some types of cancer. For example, *de novo* prostate cancer cell line culture is difficult, with only seven widely available cell lines that lack expression of many of the genetic lesions involved in this cancer. Using organoids from prostate cancer patients showed that they developed similarities to the histology of the original tumor, and contained many of the

mutations in *SPOP*, and *FOXAI* as well as *CHDI* loss, which are known to be involved in prostate cancer (Gao et al. 2014). Further these organoids demonstrated differences in responses to drugs and after 3 months culture, the organoid lines were shown to still share matching somatic mutations and transcriptomes with the original tumor. Organoids have been also been established from rare CRC tumors including neuroendocrine cancers and serrated adenomas, and grown from biopsies from metastatic disease and from circulating tumor cells (Gao et al. 2014; Yu et al. 2014, Fujii et al. 2016).

CRC organoids responded to drug treatment based on the molecular status of the original tumor (Gao et al. 2014; Van de Wetering et al. 2015). Screening of 83 drugs in these organoids confirmed that *TP53* loss of function mutants did not respond to the MDM2 inhibitor nutlin 3a, nor *RAS* mutants to EGFR inhibitors and demonstrated responsiveness of *RNF43* mutants to inhibitors of Wnt secretion. Organoids generated from liver metastases were more metastatic in xenograft culture even though the gene expression and mutational status were found to be comparable with the original tumor (Van de Wetering et al. 2015). Comparisons between a primary gastric cancer and its ovarian metastatic growth, found that the metastasis lost amplification of the *FGFR2* gene, but had gained alteration in transforming growth factor- β receptor 2 (Nadauld et al. 2014). Other research illustrated that combination treatment using pan-HER and MEK inhibitors caused cell-cycle arrest in *Kras*^{G12D} mutant CRC organoids, but cell death in *KRAS* wild-type organoids; combining this treatment with BCL-2 inhibition, surmounted this resistance, a result counter to those seen in cell lines (Verissimo et al. 2016). Screens of single compounds or co-treatments in CRC, endometrial and uterine cancer organoids have uncovered several possible original treatment strategies (Pauli et al. 2017).

A large multicentre, prospective trial (TUMOROID – NL49002.031.14) is assessing whether the drug responses of organoids can be used to evaluate treatment responses in metastatic CRC, breast or NSCLC patients. The use of organoids in patient selection for clinical trials is under examination in the SENSOR study (NL50400.031.14 EudraCT 2014-003811-13), using biopsies from metastatic CRC and NSCLC. This is of importance since it is likely that potential novel treatments

could fail if evaluated in an inappropriate patient group which is of real concern in the development of specific, targeted therapies. There are several initiatives to develop both cancer and normal organoids as resources for researchers. For example, the Hubrecht Organoid Technology (HUB) biobank, which forms a section of the Human Cancer Models Initiative, aims to generate around 1,000 models in collaboration with The National Cancer Research Institute, Cancer Research UK, and the Wellcome Trust Sanger Institute. This initiative develops and analyses tumor organoids from pancreatic, prostate, breast, CRC and lung tumors, collating patient data and drug sensitivity. It was recently reported that over 100 breast cancer organoids from primary and metastatic tumours have also been cultivated (Sachs et al. 2018).

c) Tumor Explants

Tumor explants are a type of organoid derived from small tumor fragments often cultured on a semi-solid support (Figure 2b). Using primary tumor tissue in *ex vivo* culture maintains the stromal components of the tumor and the tumor architecture (van der Kuip et al. 2006; Gu et al. 2013a; Witkiewicz et al. 2015; Karekla et al. 2017).

Cultured explants offer a route towards precision medicine because multiple drug responses can be identified and monitored within days (Ward et al. 2015), a far more acceptable time scale in comparison with PDXs or organoids. *Ex vivo* tumor explants using naive biopsy tissue could provide analogous insights to neoadjuvant clinical trials, to verify responsiveness of the primary tumor to specific therapies, and could be used to examine novel therapies, co-treatments, and treatment scheduling. Explants can survive for over a month in culture, (Leeper et al. 2011; 2012; Katz et al. 2012; Ward et al. 2015); they reflect the heterogeneity of the tumor structure, are a good model to target microenvironmental adaptations and can allow comprehensive testing of pre-clinical models in heterogeneous tumor material subtypes. If tumor growth recurs, post-treatment resistance in individual patients can be investigated if tumor tissue is available. One of the difficulties in modelling breast cancer is the heterogeneity of the disease as observed in the clinic, since

breast cancer subtypes often show differential responses to therapies. *Ex vivo* culture of unselected breast tumor explants can overcome this difficulty. Studies show that explanted breast tumor tissue conserved ER, PR and HER2 status and proliferation rates in comparison with the original primary tumor tissue, which demonstrates the preservation of many characteristics of the original tumor in the *ex vivo* model (Dean et al. 2012). Tumor explants have also been used to examine novel carbonic anhydrase inhibitors in breast and topical chemotherapy in urothelial carcinoma (Bolenz et al. 2009; Ward et al. 2015).

Studies using human breast tumor explants illustrated that inhibitors of Rac GTPases (EHT 1864), and STAT3 (Stattic) could prevent spread of breast cancers and cell proliferation at the invading edge of a tumor (Katz et al. 2012). In other work, treatment of breast cancer explants with the CDK4/6 inhibitor, PD-0332991 showed suppression of proliferation as measured by Ki67 staining, in all but a small subset of explants resistant to treatment. In these resistant tumors, lymph node metastases were also unaffected by treatment, and further research demonstrated that this was linked to the lack of the retinoblastoma (RB) tumor suppressor protein (Dean et al. 2012).

PD-0332991 has also been examined in PDA tumor explants (Witkiewicz et al. 2015). The CDK4/6 inhibitor, p16ink4a is commonly lost in PDA, but in most models and in xenografts, inhibition of CDK4/6 is a fairly ineffective treatment and resistance quickly develops. In the explant model, however, CDK4/6 inhibition suppressed proliferation in all explants tested, except for one demonstrating loss of RB; a result mirrored in PDX of the same tumors, modelled in parallel (Witkiewicz et al. 2015), suggesting differential drug responses across systems. A study in prostate cancer explants using the Jak2 inhibitor AZD 1480 (Gu et al. 2013b), demonstrated that responsive explants underwent apoptosis when nuclear Stat5a/b decreased in response to the inhibitor, while in resistant explants, it did not. Prostate tumor explants have also been used to test the effectiveness of novel Stat5a/b inhibitory compounds (Liao et al. 2015)

Explants have been used to examine the links between metabolism, hypoxia and inflammation in Barrett esophagus, a preneoplastic lesion which can progress to

esophageal adenocarcinoma (Phelan et al. 2016), and to examine the role of bile acids in gastroduodenal reflux which causes increased expression of MUC1, associated with early carcinogenic changes in this condition (Mariette et al. 2008). They have also been used in head and neck cancer to study the effectiveness of a phytochemical treatment, Lupeol (Bhattacharyya et al. 2017). Results showed a good response to Lupeol, and using explants from a cisplatin-resistant tumor, it was found that this molecule could resensitize the tumors to cisplatin (Bhattacharyya et al. 2017). In non-small cell lung carcinoma, tumor explants could be used to predict patient response to therapy and to monitor clinically relevant biomarkers (Karekla et al. 2017). Explants have been used to confirm and investigate changes between low and high grade tumors in several settings such as endometrial cancer (Cornel et al. 2012). Analysis of sarcoma development suggests that while the p53 tumor suppressor pathway may be intact, the p53 ubiquitin ligase, *MDM2*, is often amplified or overexpressed (Toledo and Wahl 2006). Although pre-clinical studies in cell lines with amplification of *MDM2* using the *MDM2* inhibitor Nutlin-3a produced positive results, only 1 patient in 20 showed a partial response in clinical trials in sarcoma patients (Muller et al. 2007; Ray-Coquard et al. 2012). Pishas et al. used sarcoma tumor explants from a range of subtypes and showed that there was no correlation between *MDM2* amplification and response to Nutlin-3a (Pishas et al. 2013) and that non-responsiveness to the drug was conferred by hypermethylation of the p53 target gene *GADD45A*. Explants have also been used in radiation studies. For example, the effectiveness of inhibiting TGF- β as a treatment or possible radiosensitiser of high grade glioma has been examined in tumor explants (Bayin et al. 2016). Results showed that most, but not all high grade gliomas, were responsive, and the authors suggest, that tumor explants could provide a rapid platform to determine patient response to this therapy and stratify treatment.

Currently, the main *in vivo* methodology for studying metastasis, generally involves the use of mouse models. Culture of tumor explants enables invasive changes in an appropriate TME to be assessed and novel therapeutics to be analyzed in patient samples in a fast and quantitative format (Ward et al. 2015) (Figure 2b). The effect of different ECM components and stromal cells can also be evaluated and

monitored in this system. The main benefits of explants in these assays are that growth/response/invasion can be monitored continuously and appraised at any time over the course of an experiment and after use the explant tissue can be fixed and analyzed.

Normal skin explants are being used to investigate tumor immunology and possible anti-tumor vaccination development. One strategy currently used is to load dendritic cells with tumor associated antigens, but the costs of generating these cells and treating them is extremely high. The use of skin tissue explants to load resident dendritic cells with tumor antigens *in situ*, has been successfully explored as an alternative method (Ruben et al. 2014). Immune checkpoint inhibition has demonstrated promise in several malignancies, but successful treatment is dependent on infiltration of CD8⁺ T cells. Prostate tumor explants were successfully treated to increase numbers of CD8⁺ T cells while decreasing numbers of immune suppressor cells, (Muthuswamy et al. 2016), illustrating their use in investigation of immunotherapeutic strategies. At present, one drawback of tumor explants is the lack of vascularization which prevents study of angiogenesis and its inhibitors. However, novel research into vascularization of tumor explants has been recently published (Bazou et al. 2016). This group has developed a method of inducing vasculature formation into xenografts of human breast cancer and melanoma, *ex vivo*, and consider that it should be possible to adapt this methodology for vascularization of human tumor explants. The advantages and disadvantages of 3D *in vitro* organoid systems are listed in Table 2.

Conclusions

It has been estimated that over 90% of drugs that make it through to clinical trials fail because of lack of efficacy and concerns over safety (Townsend et al. 2016, Ledford, 2011). Given the particularly high attrition rate of novel anti-cancer therapies during progression from pre-clinical to clinical trials, it is obvious that current testing methodologies are problematic. Better, more physiological systems are clearly needed for a) drug testing and b) patient participation in an era of more targeted treatments and personalized medicine. The 'ideal' tumor model would be able to mimic the development of malignant cells, angiogenesis, stromal development,

immune responses, metastasis, therapeutic efficacy, and progression to resistant disease. This chapter shows that there is not one specific methodology that can fulfil these criteria. Therefore more than one model system will be required to provide better translational results.

Cell lines are a suitable model for drug screening, but lead compounds need to be tested in more intricate animal models, that allow for pharmacokinetic and toxicity studies that can monitor off target effects. These *in vivo* models are useful, and GEMMs and PDXs can reflect many of the features of the tumor from which they were developed. But the time taken for tumor growth is not compatible with use as a clinical decision making tool in precision medicine. However, *in vitro* models specific to an individual patient (such as organoids or tumor explants), can be used to test drugs and guide treatment in a more specialized manner. Results from these systems are available within days and could thus prevent the use of ineffective drugs for a given patient and limit access to more expensive drugs to those likely to benefit.

Access to human tumor tissue is problematic for many scientists, but because organoids can be stored they can be used as a research resource and passed to other researchers. Organoids could also be developed from GEMM mouse models and used in cancer research. They would be particularly useful in the study of the pre-clinical stages of cancer, and in the study of cancer resurgence from residual disease. This methodology has been used to study recurrence in breast cancer, and showed that these residual cells develop to become transcriptionally divergent from both the original tumor and normal epithelium (Havas et al. 2017). Organoids can be used for high throughput drug screening assays that meet industry standards (Huang et al. 2015; Van de Wetering et al. 2015; Boehnke et al. 2016).

The most significant factor that is likely to govern the rate of success in oncology clinical trials, is matching the experimental models to the clinical malignancy. The pros and cons of experimental systems suggest that new therapeutics should be examined using several methods.

Acknowledgements

The authors MG, JM, CW, IK, AM and DA are supported by funding from the UK Engineering and Physical Sciences Research Council, through the IMPACT (Implantable Microsystems for Personalised Anti-Cancer Therapy) programme grant (EP/K-34510/1).

References

- Aparicio S, Hidalgo M, Kung AL (2015) Examining the utility of patient-derived xenograft mouse models. *Nat Rev Cancer* 15:311-316
- Arrowsmith J (2011) Trial watch: phase II failures: 2008–2010. *Nat Rev Drug Discov* 10:328-329
- Bayin NS et al (2016) Patient-specific screening using high-grade glioma explants to determine potential radiosensitization by a TGF- β small molecule inhibitor. *Neoplasia* 18:795-805
- Bazou D, Maimon N, Gruionu G, Munn LL (2016) Self-assembly of vascularized tissue to support tumor explants *in vitro*. *Integr Biol* 8:1301-1311
- Bell-McGuinn KM, Garfall AL, Bogyo M, Hanahan D, Joyce JA. (2007) Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. *Cancer Res* 67:7378-7385
- Bellmunt J et al (2010) Activity of a multitargeted chemo-switch regimen (so-rafenib, gemcitabine and metronomic capecitabine) in metastatic renal-cell carcinoma: A phase 2 study (ISOGUG-02-06). *Lancet Oncol* 11:350-357
- Beloribi-Djefaflija S, Siret C, Lombardo D (2015) Exosomal lipids induce human pancreatic tumoral MiaPaCa-2 cells resistance through the CXCR4-SDF-1 α signaling axis. *Oncoscience* 2:15–30
- Belteki G et al (2005) Conditional and inducible transgene expression in mice through the combinatorial use of Cre-mediated recombination and tetracycline induction. *Nucl Acids Res* 33:e51.
- Ben-David U et al (2017) Patient-derived xenografts undergo mouse-specific tumor evolution. *Nature Genet* 49:1567-1575
- Bhattacharyya S et al (2017) CDKN2A-p53 mediated antitumor effect of Lupeol in head and neck cancer. *Cell Oncol* 40:145-155
- Boedigheimer MJ, Freeman DJ, Kiaei P, Damore MA, Radinsky R (2013) Gene expression profiles can predict panitumumab monotherapy responsiveness in human tumor xenograft models. *Neoplasia* 15:125-132
- Boehnke K et al (2016) Assay establishment and validation of a high-throughput screening platform for three-dimensional patient-derived colon cancer organoid cultures. *J Biomol Screen* 21:931-941
- Boj SF et al (2015) Organoid models of human and mouse ductal pancreatic cancer. *Cell* 160:324-338
- Boj, SF et al (2016) Model organoids provide new research opportunities for ductal pancreatic cancer. *Mol Cell Oncology* 3:1 e1014757
- Bolenz C et al (2009) Topical chemotherapy in human urothelial carcinoma explants: a novel translational tool for preclinical evaluation of experimental intravesical therapies *European Urology* 56:504-511
- Bomken S, Fiser K, Heidenreich O, Vormoor J (2010) Understanding the cancer stem cell. *British Journal of Cancer* 103:439-445.
- Broutier et al (2017) Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. *Nature Med* 23:1424-1435
- Bruna A et al (2016) A biobank of breast cancer explants with preserved intratumor heterogeneity to screen anticancer compounds. *Cell* 167:260-274

Burdall SE, Hanby AM, Lansdown MR, Speirs V (2003) Breast cancer cell lines: friend or foe? *Breast Cancer Res* 5:89-95

Byrne AT et al (2017) Interrogating open issues in cancer precision medicine with patient-derived xenografts. *Nature Rev Cancer* 17:254–268

Capodanno Y et al (2018) Notch pathway inhibition targets chemoresistant insulinoma cancer stem cells. *Endocr Relat Cancer* 25:131-144

Caponigro G, Sellers WR (2011) Advances in the preclinical testing of cancer therapeutic hypotheses. *Nat Rev Drug Discov* 10:179-187

Chen Z et al (2012) A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. *Nature* 485:613-617

Cheung KJ, Gabrielson E, Werb Z, Ewald, AJ (2013) Collective invasion in breast cancer requires a conserved basal epithelial program. *Cell* 155:1639-1651

Clark AK et al (2013) A bioengineered microenvironment to quantitatively measure the tumorigenic properties of cancer-associated fibroblasts in human prostate cancer *Biomaterials* 34:4777-4785

Cornel KMC et al (2012) Overexpression of 17 β -hydroxysteroid dehydrogenase type 1 increases the exposure of endometrial cancer to 17 β -estradiol. *J Clin Endocrinol Metab* 97:E591-E601

Correia AL Bissell MJ (2012) The tumor microenvironment is a dominant force in multidrug resistance. *Drug Resist Update* 15:39-49

Crawford Y et al (2009) PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. *Cancer Cell* 15:21-34

Daniel VC, et al (2009) A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture *in vitro*. *Cancer Res* 69:3364-3373

Dean JL et al (2012) Therapeutic response to CDK4/6 inhibition in breast cancer defined by *ex vivo* analyses of human tumors. *Cell Cycle* 11:2756-2761

Dekkers JF et al (2013). A functional CFTR assay using primary cystic fibrosis intestinal organoids. *Nat Med* 19:939-945

Delitto D et al (2015) Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer. *Cancer Immunol Immunother* 64:1553-1563

DeRose YS et al (2011) Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. *Nat Med* 17:1514-1520

Dit Faute MA et al (2002) Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant. *Clin Exp Metastasis* 19:161-168

Drost J et al (2017) Use of CRISPR-modified human stem cell organoids to study the origin of mutational signatures in cancer. *Science* 358:234-238

Ekert JE et al (2014) Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness *in vitro* – implication for drug development. *PLoS ONE* 9(3):e92248. doi:10.1372/journal.pone.0092248

Faca VM et al (2008) A mouse to human search for plasma proteome changes associated with pancreatic tumor development. *PLoS Med* 5:e123

Fournier MV et al (2006) Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer. *Cancer Res* 66:7095-7102

Freidrich J, Seidel C, Ebner R, Kunz-Schughart LA (2009) Spheroid-based drug screen: considerations and practical approach. *Nat Protoc* 4:309-324

Fujii M et al (2016) A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis. *Cell Stem Cell* 18:827-838

Gao D et al (2014) Organoid cultures derived from patients with advanced prostate cancer. *Cell* 159:176-187

Gao D, Chen Y (2015) Organoid development in cancer genome discovery. *Curr Opin Gen Develop* 30:42-48

Gao H et al (2015) High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. *Nature Med* 21:1318-1325

Gatenby RA et al (2007) Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. *Br J Cancer* 97:646-53

Ghajar CM, et al (2013) The perivascular niche regulates breast tumour dormancy. *Nat Cell Biol* 15: 807-817

Graves EE et al (2010) Hypoxia in models of lung cancer: implications for targeted therapeutics. *Clin Cancer Res* 16:4843-4852

Gu L, Liao Z, McCue P, Trabulsi EJ, Nevalainen MT (2013a) *Ex vivo* prostate cancer explant organ culture model system for targeted drug development in prostate cancer. *J Clin Oncol Abstract* doi: 10.1200/jco.2013.31.6-suppl.110.a

Gu L et al (2013b) Pharmacologic inhibition of Jak2-Stat5 signaling by Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer. *Clin Cancer Res* 19:5658-5674

Guillaumond F et al (2013) Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. *PNAS USA* 110:3919-3924

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. *Cell* 144:646-674

Havas KM et al (2017) Metabolic shifts in residual breast cancer drive tumor recurrence. *J Clin Invest* 127:2091-2105

Heneweer M et al (2005) Co-culture of primary human mammary fibroblasts and MCF-7 cells as an *in vitro* breast cancer model. *Toxicol Sci* 83:257-263

Hensley CT et al (2016) Metabolic heterogeneity in human lung tumors. *Cell* 164:681-694

Herrmann D et al (2014) Three-dimensional cancer models mimic cell-matrix interactions in the tumour microenvironment. *Carcinogenesis* 35:1671-1679

Hesami P et al (2014) A humanized tissue-engineered *in vivo* model to dissect interactions between human prostate cancer cells and human bone. *Clin Exp Metastasis* 31:435-446

Hidalgo M et al (2011) A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. *Mol Cancer Therapeut.* 10:1311-1316

- Holzapfel BM et al (2014) Species-specific homing mechanisms of human prostate cancer metastasis in tissue engineered bone. *Biomaterials* 35:4108-4115
- Horie M et al (2012) Characterization of human lung cancer-associated fibroblasts in three-dimensional *in vitro* co-culture model. *Biochem Biophys Res Commun* 423:158-163
- Hsiao AY et al (2009) Microfluidic system for formation of PC-3 prostate cancer co-culture spheroids. *Biomaterials* 30:3020-3027
- Huang L et al (2015) Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. *Nat Med* 21:364-1371
- Huang M, Shen A, Ding J, Geng M (2014) Molecularly targeted cancer therapy: some lessons from the past decade. *Trends Pharmacol Sci* 35:41-50
- Hubert CG et al (2016) A three-dimensional organoid culture system derived from human glioblastomas recapitulates the hypoxic gradients and cancer stem cell heterogeneity of tumors found *in vivo*. *Cancer Res* 76:2465-2477
- Infanger DW et al (2013) Glioblastoma stem cells are regulated by interleukin-8 signaling in a tumoral perivascular niche. *Cancer Res* 73:7079-7089
- Ingram M et al (2010) Tissue engineered tumor models. *Biotech Histochem* 85:231-229
- Ishiguro T. Tumor-derived spheroids: relevance to cancer stem cells and clinical applications. *Cancer Science*, 108:283-289 (2017).
- Jaganathan H et al (2014) Three-dimensional *in vitro* co-culture model of breast tumor using magnetic levitation. *Sci Rep* 4:6468. doi: 10.1038/srep06468
- Julien S et al (2012) Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. *Clin Cancer Res* 18:5314-5328
- Kamb A (2005) What's wrong with our cancer models? *Nat Rev Drug Dis* 4:161-165
- Karar J, Maity A (2009) Modulating the tumor microenvironment to increase radiation responsiveness. *Cancer Biol Ther* 8:1994-2001
- Karekla E et al (2017) *Ex vivo* explant cultures of non-small cell lung carcinoma enable evaluation of primary tumor responses to anticancer therapy. *Cancer Res* 77:2029-2039
- Katz E et al (2012) Targeting of Rac GTPases blocks the spread of intact human breast cancer. *Oncotarget* 3:608-613
- Kim S, Lee EK, Kuh H (2015) Co-culture of 3D tumor spheroids with fibroblasts as a model for epithelial-mesenchymal transition *in vitro*. *Exper Cell Res* 335:187-196
- Klco JM et al (2014) Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. *Cancer Cell* 25:379-392
- Kopetz S, Lemos R, Powis G (2012) The promise of patient-derived xenografts: the best laid plans of mice and men. *Clin Cancer Res* 18:5160-5162
- Lancaster MA, Knoblich JA (2014) Organogenesis in a dish: Modeling development and disease using organoid technologies. *Science* 345:doi:10.1126/science.1247125

Lane AN, Higashi RM, Fan TW (2016) Preclinical models for interrogating drug action in human cancers using stable isotope resolved metabolomics (SIRM). *Metabolomics*. 12:118. doi:10.1007/s11306-016-1065-y

Langdon SP (2004) Isolation and culture of ovarian cancer cell lines. *Method Mol Med* 88:133-139

Lawrence MG et al (2013) A preclinical xenograft model of prostate cancer using human tumors. *Nat Protoc* 8:836-848

Ledford H (2011) 4 ways to fix the clinical trial. *Nature* 477:526-528

Ledford H (2015) CRISPR, the disruptor. *Nature* 522:20-24.

Ledford H (2016) US cancer institute to overhaul tumour cell lines. *Nature* 530:391

Leeper AD et al (2011) Long-term culture of human breast cancer specimens and their analysis using optical projection tomography. *J Vis Exp* pii3085

Leeper AD et al (2012) Determining tamoxifen sensitivity using primary breast cancer tissue in collagen-based three-dimensional culture. *Biomaterials* 33:907-915

Li L, Lu Y (2011) Optimizing a 3D culture system to study the interaction between epithelial breast cancer and its surrounding fibroblasts. *J Cancer* 2: 458-466

Liao Z et al (2015) Structure-based screen identifies a potent small molecule inhibitor of Stat5a/b with therapeutic potential for prostate cancer and chronic myeloid leukaemia. *Mol Cancer Ther* 14:1777-1793

Loessner D et al (2010) Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. *Biomaterials* 31:8494-8506

Longati P et al (2013) 3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing. *BMC Cancer* 13:95

Mariette C et al (2008) Activation of MUC1 mucin expression by bile acids in human esophageal adenocarcinomatous cells and tissues is mediated by the phosphatidylinositol 3-kinase. *Surgery* 143: 58-71

Martin JK, Patrick DR, Bissell MJ, Fournier MV (2008) Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. *PLoS ONE*. 3:e2994. <http://dx.doi.org/10.1371/journal.pone.0002994>

Martinez-Garcia R et al (2014) Transcriptional dissection of pancreatic tumors engrafted in mice. *Genome Medicine* 6:27

Matano M et al (2015) Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. *Nat Med* 21:256-262

McAllister SS, Weinberg RA (2010) Tumor-host interactions: a far-reaching relationship. *J Clin Oncol* 28:4022-4028

McCracken KW et al (2014) Modelling human development and disease in pluripotent stem-cell-derived gastric organoids. *Nature* 516:400-404

Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. *Nat Rev Cancer* 6:583-592

Mitra A, Mishra L, Li S (2015) EMT, CTCs and CSCs in tumor relapse and drug-resistance. *Oncotarget* 6:10697-10711.

Moore CB, Guthrie EH, Huang MTH, Taxman DJ (2010) Short hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown. *Methods Mol Biol* 629:141-158

Morton JJ, Bird G, Refaeli Y, Jimeno A (2016) Humanized mouse xenograft models: narrowing the tumor-microenvironment gap. *Cancer Res* 76:6153-6158

Muller CR et al (2007) Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. *Int J Cancer* 121:199-205

Muthuswamy R, Corman JM, Dahl K, Chatta GS, Kalinski P (2016) Functional reprogramming of human prostate cancer to promote local attraction of effector CD8(+) T cells. *Prostate* 76:1095-105

Nadauld LD, et al (2014) Metastatic tumor evolution and organoid modeling implicate *TGFBR2* as a cancer driver in diffuse gastric cancer. *Genome Biol*:428 <http://genomebiology.com/2014/15/8/428>

Nardella C, Lunardi A, Patnaik A, Cantley LC, Pandolfi PP. (2011) The APL paradigm and the “co-clinical trial” project. *Cancer Dis* 1:108-116

Nozaki K et al (2016) Co-culture with intestinal epithelial organoids allows efficient expansion and motility analysis of intraepithelial lymphocytes *J Gastroenterol* 51:206-213

Ocana A, Pandiella A, Siu LL, Tannock IF (2011) Preclinical development of molecular-targeted agents for cancer. *Nat Rev Clin Oncol* 8:200-209

Olive KP et al (2009) Inhibition of Hedgehog signalling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. *Science* 324:1457-1461

Pajic A et al (2000) Cell cycle activation by c-myc in a burkitt lymphoma model cell line. *Int J Cancer* 87:787-793

Pauli C et al (2017) Personalized *in vitro* and *in vivo* cancer models to guide precision medicine. *Cancer Discov* 7:462-477

Petsko GA (2010) When failure should be the option. *BMC Biol* 8: 61

Pettersen EO et al (2015) Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium, *J Enzyme Inhib Med Chem* 30:5, 689-721

Phelan JJ et al (2016), Examining the connectivity between different cellular processes in the Barrett tissue microenvironment. *Cancer Lett* 371:334-346

Pickl M, Ries CH (2009) Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. *Oncogene* 28:461-468

Pietras K, Hanahan D (2005) A multitargeted, metronomic, and maximum-tolerated dose “chemoswitch” regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. *J Clin Oncol* 23:939-952

Pishas KI et al (2014) Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling. *Cancer Res* 74:921-931

Pitteri SJ et al (2009) Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery. *PLoS ONE* 4:e7916

Politi K, Fan PD, Shen R, Zakowski M, Varmus H et al (2010) Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. *Dis Model Mech* 3:111-119

- Politi K, Pao W (2011) How genetically engineered mouse tumour models provide insights into human cancers. *J Clin Oncol* 29:2273-2281
- Pouyssegur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. *Nature* 441:437-443
- Proia DA, Kuperwasser C (2006) Reconstruction of human mammary tissues in a mouse model *Nat Protoc* 1:206-214
- Ravi M, Paramesh V, Kaviya SR, Anuradha E, Paul Solomon FDP (2014) 3D cell culture systems: Advantages and applications. *J Cell Physiol* 230:16-26.
- Royal F et al (2012) Molecular profiling of patient-derived breast cancer xenografts. *Breast Cancer Res* 14:R11
- Ray-Coquard I et al. (2012) Effect of the MDM2 antagonist R7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma; an exploratory proof-of-mechanism study. *Lancet Oncology* 13:1133-1140
- Riemer P et al (2017) Oncogenic β -catenin and PIK3CA instruct network states and cancer phenotypes in intestinal organoids. *J Cell Biol* 216:1567-1577
- Riffle S, Naresh P, Albert M, Hegde RS (2017) Linking hypoxia, DNA damage and proliferation in multicellular tumor spheroids. *BMC Cancer* 17:338 DOI 10.1186/s12885-017-3319-0
- Roper J et al (2017) *In vivo* genome editing and organoid transplantation models of colorectal cancer and metastasis. *Nature Biotechnol* 35:569-576
- Ruben JM et al (2014) *In situ* loading of skin dendritic cells with apoptotic bleb-derived antigen for the induction of tumor-directed immunity. *Oncoimmunology* 3:7e946360, DOI:10.4161/21624011.2014.946360
- Sachs N, Clevers H (2014) Organoid cultures for the analysis of cancer phenotypes. *Curr Opin Gen Develop* 24: 68-73
- Sachs N et al (2018) A living biobank of breast cancer organoids captures disease heterogeneity. *Cell* 172: 1-14
- Sander JD, Joung JK (2014) CRISPR-Cas systems for editing, regulating and targeting genomes. *Nature Biotechnol* 32:347-355
- Sato T et al (2011) Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma and Barrett's epithelium. *Gastroent* 141:1762-1772
- Saunders T (2011) Inducible transgenic mouse models. *Methods Mol Biol* 693:103-115
- Sausville EA, Burger AM (2006) Contribution of human tumor xenografts to anticancer drug development. *Cancer Res* 66:3351-3354
- Schmeichel KL, Bissell MJ (2003) Modeling tissue-specific signalling and organ function in three dimensions. *J Cell Sci* 116: 2377-2388
- Schutte M et al (2017) Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors *Nat Commun* 8:14262
- Schwank G et al (2013) Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. *Cell Stem Cell* 13:653-658

Sethi T et al (1999) Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. *Nat Med* 5:662-668

Sharpless NE, Depinho RA (2006) The mighty mouse: genetically engineered mouse models in cancer drug development. *Nature Rev Drug Discov* 5:741-754

Simian M, Bissell MJ (2017) Organoids: A historical perspective of thinking in three dimensions. *J Cell Biol.* 216:31-40

Singh M et al (2010) Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. *Nature Biotechnol* 28:585-593

Singh M, Ferrara N (2012) Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. *Nature Biotechnol* 30:648-657

Singh M, Close DA, Mukundan S, Johnston PA, Sant S (2015) Production of uniform 3D microtumors in hydrogel microwell arrays for measurement of viability, morphology and signalling pathway activation. *Assay Drug Dev Technol* 13:570-583

Singh M, Mukundan S, Jaramillo M, Oesterreich S, Sant S (2016) Three-dimensional breast cancer models mimic hallmarks of size-induced tumor progression. *Cancer Res* 76:3732-3743

Siolas D, Hannon GJ (2013) Patient derived tumor xenografts: transforming clinical samples into mouse models. *Cancer Res* 73:5315-319

Stewart E et al (2017) Orthotopic patient-derived xenografts of paediatric solid tumours, *Nature* 549:96-100

Straussman R et al (2012) Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. *Nature* 487:500-504

Tentler JJ et al (2012). Patient-derived tumour xenografts as models for oncology drug development. *Nat Rev Clin Oncol* 9:338-350

Thibaudeau L et al (2014) A tissue-engineered humanized xenograft model of human breast cancer metastasis to bone. *Dis Model Mech* 7:299-309

Timpson P et al (2011) Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53. *Cancer Res* 71: 747-757

Toledo F, Wahl GM (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. *Nat Rev Cancer* 6:909-923

Townsend EC et al (2016) The public repository of xenografts enables discovery and randomized phase II-like trials in mice. *Cancer Cell* 29:574-586

van der Kuip H et al (2006) Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. *BMC Cancer* 6: 86 doi:10.1186/1471-2407-6-86

van de Wetering M et al (2015) Prospective derivation of a 'Living Organoid Biobank' of colorectal cancer patients *Cell* 161:933-945

Verissimo CS, et al (2015) Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening *eLife*, 5: 10.7554/eLife.18489

Verjans E, Doijen J, Luyten W, Landuyt B, Schoofs L (2017) Three-dimensional cell culture models for anticancer drug screening: Worth the effort? *J Cell Physiol* 1-11 doi.org/10.1002/jcp26052

Vudattu NK et al (2014) Humanized mice as a model for aberrant responses in human T cell immunotherapy. *J Immunol* 193:587-596

Wang J et al (2010) A novel orthotopic and metastatic mouse model of breast cancer in human mammary microenvironment. *Breast Cancer Res Treat* 120:337-344

Wang X, et al (2018) Enrichment of glioma stem cell-like cells on 3D porous scaffolds composed of different extracellular matrix. *Biochem Biophys Res Comm* 498: 1052-1057

Ward C et al (2013) New strategies for targeting the hypoxic tumour microenvironment in breast cancer. *Cancer Treatment Reviews*, 39:171-179

Ward C et al (2015) Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models. *Oncotarget* 6:24856-2485670

Ware MJ et al (2016) Generation of an *in vitro* 3D PDAC stromal rich spheroid model. *Biomaterials* 108: 129-142

Weeber F et al (2015) Preserved genomic diversity in organoids cultured from biopsies of colorectal cancer metastases *PNAS USA* 112:13308-13311

Werner-Klein M et al (2014) Immune humanization of immunodeficient mice using diagnostic bone marrow aspirates from carcinoma patients. *PLoS One* 2014;9: e97860. 6158

Witkiewicz AK et al (2015) Selective impact of CDK4/6 suppression of patient-derived models of pancreatic cancer. *Oncotarget* 6:15788-15801

Xie H et al (2014) Targeting lactate dehydrogenase-A inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor initiating cells. *Cell Metabolism* 19:795-780

Yamada KM, Cukierman E (2007) Modeling tissue morphogenesis and cancer in 3D. *Cell* 130: 601-610

Yu M (2014) *Ex vivo* culture of circulating breast tumor cells for individualized testing of drug susceptibility. *Science* 345:216-220

Zamboni, WC et al (2012) Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. *Clin. Cancer Res* 18:3229-3241

Zhang X et al (2013) A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. *Cancer Res* 73:4885-4897

Table 1

	Strengths	Weaknesses
Mouse Xenografts	<ul style="list-style-type: none"> - allow <i>in vivo</i> monitoring of tumor growth, drug toxicity and efficacy - reflect <i>in vivo</i> pH and oxygen gradients 	<ul style="list-style-type: none"> - limited metastatic models - compromised immune responses - murine stromal elements
GEMMs	<ul style="list-style-type: none"> - share the genetic heterogeneity and histopathology of human tumors - replicate both the TME and stroma more accurately than xenografts 	<ul style="list-style-type: none"> - model is still murine
PDXs	<ul style="list-style-type: none"> - pathology, growth and metastatic outcomes closely correspond to the original tumor - preserve the heterogeneity of different cancers - useful in cases where primary material is rare 	<ul style="list-style-type: none"> - availability/access to fresh tumor tissue is a limiting factor - passaging is time consuming - stromal tumor elements lost over time - rate of engraftment is poor for some cancer types - deficiency in immune response

Table 1

Listing the advantages and disadvantages of *in vivo* tumor models.

Table 2

	Set-up Methods	Strengths	Weaknesses
Spheroids	Spheroids are set up using cancer cell lines from 2D culture. (various methods are illustrated in Figure 1). These can be grown from genetically modified cells and can incorporate other cell types	<ul style="list-style-type: none"> - exhibit cell/cell and cell/ECM interactions - mimic <i>in vivo</i> oxygen, pH and metabolic gradients - useful in high-throughput drug screening assays 	<ul style="list-style-type: none"> - use cancer cell lines, which can lose the biological traits of the cancer from which they derived
Organoids	Organoids are developed from tissue samples/cancer stem cells and contain the cell types found in the tissue of origin. These cells can be genetically modified, and cultured with other cell types	<ul style="list-style-type: none"> - biologically stable - can be frozen for later use - allow the culture of tumors from individual patients - can provide tissues for the study of rare cancers or where cell line models are scarce - useful in high-throughput drug screening assay 	<ul style="list-style-type: none"> - clonal drift may occur over time - high costs - lack tumor stroma, vasculature and immune cell interactions
Explants	Explants are derived from human-tumor tissue – usually biopsies. Genetic modification is difficult, but they can be cultured with other cell types	<ul style="list-style-type: none"> - maintain the stromal components and tissue architecture of the primary tumor - good model to target microenvironmental adaptations - maintain histology and proliferation rates of the original tumor - growth/response/invasion can be monitored continuously 	<ul style="list-style-type: none"> - lack of vascularization prevents the study of angiogenesis and its inhibition

Table 2

Listing the advantages and disadvantages of 3D *in vitro* tumor models.

Figure Legends

Figure 1. Illustrating the physiological features of spheroids and several of the methods used to culture them. a) a schematic diagram of the different layers of a spheroid culture b) shows immunohistochemical staining for carbonic anhydrase IX, which is upregulated by hypoxia and indicates the hypoxic region c) spinner flask spheroid culture d) alginate culture e) hanging drop method.

Figure 2. Illustrating 3D invasion assays using human breast cancer cell spheroids and human breast cancer tumor explants. a) spheroids grown in spinner flasks and embedded in collagen I. Images were obtained at 0 h and 96h of culture. b) tumor explants prepared by trimming fat from biopsy samples and cutting into pieces approx. 1mm³, before embedding in collagen I. Images were obtained at 0h and 120h of culture. Images were acquired using phase contrast microscopy. Original magnification x 25.

